Cargando…

The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.

The serum diagnostic value of the foeto-acinar pancreatic protein (FAP protein), an oncofoetal pancreatic antigen, was tested in 201 patients. Of these, 112 suffered from malignant disease (57 patients had pancreatic carcinoma and 55, extra-pancreatic malignancies) and 89 had benign disease (49 pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujii, Y., Albers, G. H., Carre-Llopis, A., Escribano, M. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1987
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001829/
https://www.ncbi.nlm.nih.gov/pubmed/3479995
_version_ 1782135675981660160
author Fujii, Y.
Albers, G. H.
Carre-Llopis, A.
Escribano, M. J.
author_facet Fujii, Y.
Albers, G. H.
Carre-Llopis, A.
Escribano, M. J.
author_sort Fujii, Y.
collection PubMed
description The serum diagnostic value of the foeto-acinar pancreatic protein (FAP protein), an oncofoetal pancreatic antigen, was tested in 201 patients. Of these, 112 suffered from malignant disease (57 patients had pancreatic carcinoma and 55, extra-pancreatic malignancies) and 89 had benign disease (49 patients with hepato-pancreato-biliary disease and 40 with other benign disease). FAP protein was measured by a competitive radioimmunoassay. In this technique, the normal cut-off level was 10% inhibition. This was deducted from values in 32 normal sera. FAP protein levels superior to 10% inhibition were found in 86% of patients with pancreatic cancer, in 31% with non-pancreatic malignancy, in 69% with benign hepato-pancreato-biliary disease and in 20% with other benign diseases. Accordingly, sensitivity of FAP protein for pancreatic carcinoma was 86% and specificity, 66%. However, high FAP protein levels (greater than 30% inhibition) were almost exclusively seen in patients with pancreatic cancer. At this cut-off level, specificity increased to 95% but sensitivity decreased to 51%. Determination of the carbohydrate antigen CA19/9 was made in parallel by a commercially available assay. At the cut-off level of 37 u ml-1, CA19/9 in our serum panel had a sensitivity of 74% for pancreatic carcinoma and a specificity of 88%. In pancreatic cancer 55 out of 57 patients had elevated levels of either FAP protein or CA19/9 (sensitivity; 96%).
format Text
id pubmed-2001829
institution National Center for Biotechnology Information
language English
publishDate 1987
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20018292009-09-10 The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9. Fujii, Y. Albers, G. H. Carre-Llopis, A. Escribano, M. J. Br J Cancer Research Article The serum diagnostic value of the foeto-acinar pancreatic protein (FAP protein), an oncofoetal pancreatic antigen, was tested in 201 patients. Of these, 112 suffered from malignant disease (57 patients had pancreatic carcinoma and 55, extra-pancreatic malignancies) and 89 had benign disease (49 patients with hepato-pancreato-biliary disease and 40 with other benign disease). FAP protein was measured by a competitive radioimmunoassay. In this technique, the normal cut-off level was 10% inhibition. This was deducted from values in 32 normal sera. FAP protein levels superior to 10% inhibition were found in 86% of patients with pancreatic cancer, in 31% with non-pancreatic malignancy, in 69% with benign hepato-pancreato-biliary disease and in 20% with other benign diseases. Accordingly, sensitivity of FAP protein for pancreatic carcinoma was 86% and specificity, 66%. However, high FAP protein levels (greater than 30% inhibition) were almost exclusively seen in patients with pancreatic cancer. At this cut-off level, specificity increased to 95% but sensitivity decreased to 51%. Determination of the carbohydrate antigen CA19/9 was made in parallel by a commercially available assay. At the cut-off level of 37 u ml-1, CA19/9 in our serum panel had a sensitivity of 74% for pancreatic carcinoma and a specificity of 88%. In pancreatic cancer 55 out of 57 patients had elevated levels of either FAP protein or CA19/9 (sensitivity; 96%). Nature Publishing Group 1987-10 /pmc/articles/PMC2001829/ /pubmed/3479995 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Fujii, Y.
Albers, G. H.
Carre-Llopis, A.
Escribano, M. J.
The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.
title The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.
title_full The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.
title_fullStr The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.
title_full_unstemmed The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.
title_short The diagnostic value of the foetoacinar pancreatic (FAP) protein in cancer of the pancreas; a comparative study with CA19/9.
title_sort diagnostic value of the foetoacinar pancreatic (fap) protein in cancer of the pancreas; a comparative study with ca19/9.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001829/
https://www.ncbi.nlm.nih.gov/pubmed/3479995
work_keys_str_mv AT fujiiy thediagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199
AT albersgh thediagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199
AT carrellopisa thediagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199
AT escribanomj thediagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199
AT fujiiy diagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199
AT albersgh diagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199
AT carrellopisa diagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199
AT escribanomj diagnosticvalueofthefoetoacinarpancreaticfapproteinincancerofthepancreasacomparativestudywithca199